Zopiclone (Imovane) 7.5mg, 3.75mg

Description

Buy Zopiclone Online

Short term treatment of insomnia, including difficulties in falling asleep, nocturnal awakening and early awakening, transient, situational or chronic insomnia, and insomnia secondary to psychiatric disturbances, in situations where the insomnia is debilitating or is causing severe distress for the patient.

Zopiclone, sold under the brand name Imovane among others, is a nonbenzodiazepine used to treat difficulty sleeping. Zopiclone is molecularly distinct from benzodiazepine drugs and is classed as a cyclopyrrolone.

Dependence and withdrawal effects with zopiclone do occur, although rarely. These effects can occur in people without prior substance dependence and who are taking the recommended dose. The duration of treatment with zopiclone should be limited to ≤ 4 weeks. Dose tapering on withdrawal may be necessary if treatment is continued for a longer period.

Zopiclone (Imovane) is indicated for the short-term treatment of insomnia and appears to be associated with a very low risk of dependence, rebound insomnia, and withdrawal problems. Nevertheless some individuals do become dependent on zopiclone, and many of these have not experienced substance dependence or abuse previously. The approved data sheet for Imovane advises no more than 4 weeks continuous treatment, and a maximum dose of 7.5mg (1 tablet) a day.

Zopiclone reduces day time anxiety; has low frequency of rebound insomnia

Indicators of the propensity for dependence with a hypno-sedative such as zopiclone are day time anxiety and rebound insomnia. A study comparing 4 weeks’ treatment with zopiclone 7.5mg, triazolam 0.5mg and placebo in patients with generalised anxiety disorder found significantly (p < 0.05) lower mean scores for anxiety, on the Hamilton Anxiety Rating Scale, for patients taking zopiclone (n=30) than for those given triazolam (n=30). The scores were 18.2 with zopiclone and 22.4 with triazolam. In the withdrawal phase of the study, zopiclone was associated with a lower frequency and lesser intensity of rebound insomnia following abrupt discontinuation than triazolam.

Withdrawal effects & dependence may occur & are being under-reported

At June 1997, the WHO database held 46 reports of dependence and 42 of withdrawal syndrome with zopiclone. From March 1994 to June 1997, Rhône-Poulenc Rorer received 17 spontaneous reports of dependence and 13 of withdrawal syndrome or symptoms with zopiclone.